Company / Cost of Revenue
Theravance Biopharma, Inc. Cost of Revenue History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.0M
FY2017
5-year range
-
FY2016-FY2017
Trend
+108.4%
vs FY2016
Sector context
#74 of 85
Health Care
What the data says
Theravance Biopharma, Inc.'s cost of revenue of $6M is lower than 87% of companies in the Health Care sector (FY2017).
Based on SEC 10-K filings.
$6M in FY2017.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 85This company $6.0M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- In FY2017, cost of revenue increased 108.4% year-over-year.
- Ranks #74 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $6.0M | +108.4% |
| FY2016 | $2.9M | - |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026